HRP20050033A2 - 1-phenylalkyl-piperazines - Google Patents
1-phenylalkyl-piperazinesInfo
- Publication number
- HRP20050033A2 HRP20050033A2 HR20050033A HRP20050033A HRP20050033A2 HR P20050033 A2 HRP20050033 A2 HR P20050033A2 HR 20050033 A HR20050033 A HR 20050033A HR P20050033 A HRP20050033 A HR P20050033A HR P20050033 A2 HRP20050033 A2 HR P20050033A2
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- group
- alkynyl
- alkenyl
- aryl
- Prior art date
Links
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- -1 R3 is H Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000004671 dialkylaminothiocarbonyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000862 serotonergic effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 210000001635 urinary tract Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Spojevi formule I(R i R1 predstavljaju širok izbor supstitutora, Q je CO, CHOH ili CHOR2, R2 je alkil, alkenil, alkinil ili cikloalkil grupa, svaka opcijski supstituirana, ili je alkanoil, alkanoiloksi, aminokarbonil, alkilaminokarbonil, dialkilaminokarbonil, aminotiokarbonil, alkilaminotiokarbonilili dialkilaminotiokarbonil, R3 je H, alkil, alkenil, alkinil, cikloalkil, aril ili heterociklična grupa, svaka opcijski supstituirana, n je 1 ili 2,A je veza ili metilenska ili etilenska grupa, i R4 je aril ili heteroaril grupa, od kojih je svaka opcijski supstituirana) imaju afinitet prema serotoninergijskim receptorima. Ovi spojevi i njihovi enatiomeri, dijastereomeri, N-piperazin oksidi, polimorfi, solvati i farmaceutski prihvatljive soli korisni su za tretman pacijenata s neuromuskularnomdisfunkcijom donjeg urinarnog trakta i srodnih bolesti, povezanih s aktivnošću receptora 5-HT1A.The compounds of formula I (R and R1 represent a wide variety of substituents, Q is CO, CHOH or CHOR2, R2 is an alkyl, alkenyl, alkynyl or cycloalkyl group, each optionally substituted, or is alkanoyl, alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarinylcarbonyl dialkylaminothiocarbonyl, R3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, each optionally substituted, n is 1 or 2, A is a bond or a methylene or ethylene group, and R4 is an aryl or heteroaryl group, each of which is optionally substituted) have affinity for serotonergic receptors. These compounds and their enantiomers, diastereomers, N-piperazine oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful for the treatment of patients with neuromuscular dysfunction of the lower urinary tract and related diseases associated with 5-HT1A receptor activity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002MI001327A ITMI20021327A1 (en) | 2002-06-14 | 2002-06-14 | NEW OSSIALCHILPIPERAZINE |
| PCT/EP2003/006289 WO2003106443A1 (en) | 2002-06-14 | 2003-06-16 | 1-phenylalkyl-piperazines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050033A2 true HRP20050033A2 (en) | 2006-11-30 |
Family
ID=29727276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050033A HRP20050033A2 (en) | 2002-06-14 | 2005-01-12 | 1-phenylalkyl-piperazines |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1549627A1 (en) |
| JP (1) | JP2006502102A (en) |
| KR (1) | KR20050055628A (en) |
| CN (1) | CN1659155A (en) |
| AU (1) | AU2003246434A1 (en) |
| BR (1) | BR0311804A (en) |
| CA (1) | CA2489449A1 (en) |
| EA (1) | EA200500024A1 (en) |
| HR (1) | HRP20050033A2 (en) |
| IL (1) | IL165569A0 (en) |
| IT (1) | ITMI20021327A1 (en) |
| MX (1) | MXPA04012489A (en) |
| NO (1) | NO20050147L (en) |
| NZ (1) | NZ537470A (en) |
| PL (1) | PL372702A1 (en) |
| RS (1) | RS109004A (en) |
| TW (1) | TW200406394A (en) |
| WO (1) | WO2003106443A1 (en) |
| ZA (1) | ZA200500317B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7071197B2 (en) * | 2002-06-14 | 2006-07-04 | Recordati S.A. | N,N-disubstituted diazocycloalkanes |
| US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
| MX2009012331A (en) * | 2007-05-14 | 2010-02-10 | Sk Holdings Co Ltd | Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound. |
| EP3113768B1 (en) * | 2014-03-05 | 2018-09-26 | Universita' Degli Studi Di Pavia | Use of arylalkanolamines as sigma-1 receptor antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5826348B2 (en) * | 1974-07-01 | 1983-06-02 | 住友化学工業株式会社 | Method for producing new benzisoxazole derivatives |
| FR2527605A1 (en) * | 1982-05-25 | 1983-12-02 | Fordonal Sa | PIPERAZINE DERIVATIVES, MANUFACTURING PROCESS AND RESULTING MEDICINAL PRODUCTS |
| GB9021535D0 (en) * | 1990-10-03 | 1990-11-14 | Wyeth John & Brother Ltd | Piperazine derivatives |
| GB9022820D0 (en) * | 1990-10-19 | 1990-12-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
| GB9125900D0 (en) * | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
| JP3523887B2 (en) * | 1992-03-09 | 2004-04-26 | 武田薬品工業株式会社 | Condensed heterocyclic ketone derivative, production method thereof, intermediate and agent |
| NZ250609A (en) * | 1992-12-28 | 1995-07-26 | Sankyo Co | Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments |
| GB9300195D0 (en) * | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| GB9419024D0 (en) * | 1994-09-21 | 1994-11-09 | Wyeth John & Brother Ltd | Bicyclic carboxamides |
| GB9514384D0 (en) * | 1995-07-13 | 1995-09-13 | American Home Prod | Medical treatment |
| UA66370C2 (en) * | 1997-12-16 | 2004-05-17 | Lilly Co Eli | Arylpiperazines having activity to setotonin 1 receptors |
-
2002
- 2002-06-14 IT IT2002MI001327A patent/ITMI20021327A1/en unknown
-
2003
- 2003-06-16 JP JP2004513275A patent/JP2006502102A/en active Pending
- 2003-06-16 KR KR1020047020369A patent/KR20050055628A/en not_active Application Discontinuation
- 2003-06-16 WO PCT/EP2003/006289 patent/WO2003106443A1/en not_active Application Discontinuation
- 2003-06-16 EA EA200500024A patent/EA200500024A1/en unknown
- 2003-06-16 PL PL03372702A patent/PL372702A1/en unknown
- 2003-06-16 BR BR0311804-5A patent/BR0311804A/en not_active IP Right Cessation
- 2003-06-16 CA CA002489449A patent/CA2489449A1/en not_active Abandoned
- 2003-06-16 EP EP03759960A patent/EP1549627A1/en not_active Withdrawn
- 2003-06-16 MX MXPA04012489A patent/MXPA04012489A/en unknown
- 2003-06-16 CN CN038136759A patent/CN1659155A/en active Pending
- 2003-06-16 AU AU2003246434A patent/AU2003246434A1/en not_active Abandoned
- 2003-06-16 NZ NZ537470A patent/NZ537470A/en unknown
- 2003-06-16 TW TW092116294A patent/TW200406394A/en unknown
- 2003-06-16 RS YUP-1090/04A patent/RS109004A/en unknown
-
2004
- 2004-12-06 IL IL16556904A patent/IL165569A0/en unknown
-
2005
- 2005-01-11 NO NO20050147A patent/NO20050147L/en not_active Application Discontinuation
- 2005-01-12 HR HR20050033A patent/HRP20050033A2/en not_active Application Discontinuation
- 2005-01-13 ZA ZA200500317A patent/ZA200500317B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL165569A0 (en) | 2006-01-15 |
| NO20050147L (en) | 2005-03-14 |
| MXPA04012489A (en) | 2005-06-08 |
| CN1659155A (en) | 2005-08-24 |
| NZ537470A (en) | 2006-06-30 |
| KR20050055628A (en) | 2005-06-13 |
| NO20050147D0 (en) | 2005-01-11 |
| BR0311804A (en) | 2005-03-29 |
| AU2003246434A1 (en) | 2003-12-31 |
| ITMI20021327A1 (en) | 2003-12-15 |
| EP1549627A1 (en) | 2005-07-06 |
| TW200406394A (en) | 2004-05-01 |
| JP2006502102A (en) | 2006-01-19 |
| CA2489449A1 (en) | 2003-12-24 |
| WO2003106443A1 (en) | 2003-12-24 |
| RS109004A (en) | 2007-02-05 |
| PL372702A1 (en) | 2005-07-25 |
| ZA200500317B (en) | 2006-11-29 |
| EA200500024A1 (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE377589T1 (en) | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | |
| TW200517109A (en) | Substituted pyridinones | |
| RS20050195A (en) | Heterocyclic substituted piperazines for the treatment of schizophrenia | |
| EA200400467A1 (en) | 3-AZABICYCLO (3.1.0) DERIVATIVES OF HEXANE AS ANTAGONISTS OPIOID RECEPTOR | |
| MY128367A (en) | Piperazine derivatives useful as ccr5 antagonists | |
| EP1705176A4 (en) | Carboxamide derivative and use thereof | |
| ATE406360T1 (en) | ANTAGONISTS OF OPIOID RECEPTORS | |
| MY143834A (en) | Thrombin receptor antagonists | |
| GEP20063958B (en) | 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists | |
| MXPA06000716A (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors. | |
| HRP20050933A2 (en) | Organic compounds | |
| MX2010005753A (en) | Isoxazolo-pyrazine derivatives. | |
| ATE464286T1 (en) | CYCLOPROPANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | |
| MXPA05011710A (en) | Fused pyrimidine derivatives with crf activity. | |
| ATE556712T1 (en) | A2A ANTAGONISTS FOR THE TREATMENT OF MOTOR DISORDERS | |
| NO20063230L (en) | CRF receptor antagonists and methods for their preparation | |
| DE69838662D1 (en) | Morphine derivatives and their medical use | |
| MXPA02011417A (en) | Substituted 1 aminoalkyl lactams and their use as muscarinic receptor antagonists. | |
| EP1553084A4 (en) | Piperidine derivative, process for producing the same, and use | |
| MXPA02011418A (en) | Substituted 1 aminoalkyl lactams and their use as muscarinic receptor antagonists. | |
| HRP20050033A2 (en) | 1-phenylalkyl-piperazines | |
| DK0733051T3 (en) | Bicyclic heterocyclic compounds as neurokinin A antagonists | |
| EP1473295A4 (en) | Fused bicyclic pyrimidine derivatives | |
| UA84300C2 (en) | HEXA- AND OCTAHYDRO-PYRIDO[1,2-a]PYRAZINE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY | |
| WO2008136377A1 (en) | Bicyclic heterocyclic compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20060523 Year of fee payment: 4 |
|
| A1OB | Publication of a patent application | ||
| OBST | Application withdrawn |